Vanguard Global Advisers’s Edesa Biotech EDSA Stock Holding History

Vanguard Global Advisers’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.32K	Hold	162	–	–	﹤0.01%	3613
2026 Q1	$847	Buy	+162	New	+$486	﹤0.01%	3641

Other funds holding EDSA

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Global Advisers's EDSA Position: Q2 2026 in Review

Vanguard Global Advisers held its Edesa Biotech (EDSA) position steady in Q2 2026 at 162 shares worth $1.32K. The position accounts for ﹤0.01% of the portfolio, ranked #3613.

Vanguard Global Advisers first reported a position in EDSA in Q1 2026 and has held it in 2 quarters since. 30 funds tracked by Wall St. Rank hold EDSA as of Q2 2026.

Vanguard Global Advisers held 162 shares of Edesa Biotech worth $1.32K as of Q2 2026.
Vanguard Global Advisers left its Edesa Biotech share count unchanged in Q2 2026.
Edesa Biotech made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3613 holding.
Vanguard Global Advisers first reported a position in Edesa Biotech in Q1 2026 and has held it in 2 quarters since.
30 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.